Combination Therapies in Psoriasis

The presentation discusses combination therapies for psoriasis, emphasizing the need for these approaches when monotherapy fails. The speaker notes that while there are no FDA-approved indications for combining therapies in patients already on biologics, clinicians often do so to enhance efficacy, reduce immunogenicity, and address comorbidities. Emphasizing the complex interplay of genetic and environmental factors in psoriasis, the speaker highlights the variability in cytokine involvement, suggesting that no single biologic can target all contributing factors effectively. Different combination strategies are explored, including pairing agents with distinct mechanisms of action to maximize efficacy while minimizing toxicity. Factors influencing treatment decisions include patient history, comorbidities, tolerability concerns, and the necessity to address both skin symptoms and accompanying conditions. Specific examples are discussed, like using methotrexate with infliximab or other biologics to enhance response and decrease immunogenicity. The importance of ongoing safety monitoring is also underscored, advocating for close observation of the drug with the highest toxicity concerns when combining therapies. The key takeaway is that while monotherapy is ideal, combination therapy should be considered based on patient-specific factors, ensuring that treatments are effective and safe in the long term.